These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 29649671)
1. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Willems LM; Richter S; Watermann N; Bauer S; Klein KM; Reese JP; Schöffski O; Hamer HM; Knake S; Rosenow F; Strzelczyk A Epilepsy Behav; 2018 Jun; 83():28-35. PubMed ID: 29649671 [TBL] [Abstract][Full Text] [Related]
2. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262 [TBL] [Abstract][Full Text] [Related]
3. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Hamer HM; Spottke A; Aletsee C; Knake S; Reis J; Strzelczyk A; Oertel WH; Rosenow F; Dodel R Epilepsia; 2006 Dec; 47(12):2165-72. PubMed ID: 17201718 [TBL] [Abstract][Full Text] [Related]
4. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Strzelczyk A; Bergmann A; Biermann V; Braune S; Dieterle L; Forth B; Kortland LM; Lang M; Peckmann T; Schöffski O; Sigel KO; Rosenow F Epilepsy Behav; 2016 Nov; 64(Pt A):75-82. PubMed ID: 27732920 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of costs of epilepsy using an electronic practice management software in Germany. Noda AH; Hermsen A; Berkenfeld R; Dennig D; Endrass G; Kaltofen J; Safavi A; Wiehler S; Carl G; Meier U; Elger CE; Menzler K; Knake S; Rosenow F; Strzelczyk A Seizure; 2015 Mar; 26():49-55. PubMed ID: 25799902 [TBL] [Abstract][Full Text] [Related]
7. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Riechmann J; Strzelczyk A; Reese JP; Boor R; Stephani U; Langner C; Neubauer BA; Oberman B; Philippi H; Rochel M; Seeger J; Seipelt P; Oertel WH; Dodel R; Rosenow F; Hamer HM; Epilepsia; 2015 Sep; 56(9):1388-97. PubMed ID: 26235849 [TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States. Fishman J; Martin M; Labiner DM; Lew CR; Johnson BH Epilepsy Behav; 2019 Oct; 99():106331. PubMed ID: 31399339 [TBL] [Abstract][Full Text] [Related]
9. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs. Groth A; Wilke T; Borghs S; Gille P; Joeres L Ger Med Sci; 2017; 15():Doc09. PubMed ID: 28638313 [No Abstract] [Full Text] [Related]
10. Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020. Willems LM; Hochbaum M; Zöllner JP; Schulz J; Menzler K; Langenbruch L; Kovac S; Knake S; von Podewils F; Hamacher M; Hamer HM; Reese JP; Frey K; Rosenow F; Strzelczyk A Epilepsia; 2022 Jun; 63(6):1591-1602. PubMed ID: 35305026 [TBL] [Abstract][Full Text] [Related]
11. Management of focal epilepsy in adults treated with polytherapy in France: the direct cost of drug resistance (ESPERA study). de Zélicourt M; de Toffol B; Vespignani H; Laurendeau C; Lévy-Bachelot L; Murat C; Fagnani F Seizure; 2014 May; 23(5):349-56. PubMed ID: 24560531 [TBL] [Abstract][Full Text] [Related]
12. Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: An analysis from the National Health and Wellness Survey. Gupta S; Kwan P; Faught E; Tsong W; Forsythe A; Ryvlin P Epilepsy Behav; 2016 Feb; 55():146-56. PubMed ID: 26773686 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Strzelczyk A; Schubert-Bast S; Reese JP; Rosenow F; Stephani U; Boor R Epilepsy Behav; 2014 May; 34():86-91. PubMed ID: 24727467 [TBL] [Abstract][Full Text] [Related]
15. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study. Borghs S; Thieffry S; Noack-Rink M; Dedeken P; Hong LS; Byram L; Logan J; Chan J; Kiri V BMC Neurol; 2017 Mar; 17(1):59. PubMed ID: 28335764 [TBL] [Abstract][Full Text] [Related]
16. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014 [TBL] [Abstract][Full Text] [Related]
17. Cost of epilepsy care in a Nigerian tertiary hospital. Sanya EO; Kolo PM; Adekeye A; Mustapha K; Ademiluyi BA; Ajayi K Niger Postgrad Med J; 2013 Dec; 20(4):266-71. PubMed ID: 24633267 [TBL] [Abstract][Full Text] [Related]
18. Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. Cramer JA; Wang ZJ; Chang E; Copher R; Cherepanov D; Broder MS Epilepsy Behav; 2015 Mar; 44():40-6. PubMed ID: 25635369 [TBL] [Abstract][Full Text] [Related]
19. General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data. Willems LM; Hamer HM; Knake S; Rosenow F; Reese JP; Strzelczyk A Appl Health Econ Health Policy; 2019 Oct; 17(5):707-722. PubMed ID: 31161366 [TBL] [Abstract][Full Text] [Related]
20. Cost of epilepsy care in a Nigerian tertiary hospital. Sanya EO; Kolo PM; Adekeye A; Mustapha K; Ademiluyi BA; Ajayi K Niger Postgrad Med J; 2013 Sep; 20(3):218-22. PubMed ID: 24287754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]